Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nexell To Use Peer-Reviewed Articles To Demonstrate Cytonex Diagnostic Use

This article was originally published in The Gray Sheet

Executive Summary

Nexell Therapeutics plans to use studies published in peer-reviewed journal articles to support marketing efforts for its Cytonex immunocytochemistry (ICC) staining kit for in vitro diagnostic use.

You may also be interested in...



WLF Decision Opens Door To Off-Label Promotion With Journal Reprints

Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.

Nexell Planning To Seek Labeling Expansion For Isolex 300i In 2001

Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.

Baxter To Distribute Ceprate During Cellpro Bankruptcy Until Isolex Approval

Baxter will distribute Cellpro's Ceprate stem cell concentration system worldwide pending approval of Nexell's Isolex stem cell collection system under a bankruptcy plan for CellPro.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel